Magenta

$7.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Magenta

Magenta Therapeutics, Inc is a clinical-stage biotechnology company. The Company is developing medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. The Company is developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies and genetic diseases. The Company is also developing a portfolio of biologics, including antibody drug conjugates, small molecules and a cell therapy. The Company’s products include MGTA-145, CD45-ADC, MGTA-456 and MGTA-117.

Stock Analysis

last close $7.4
1-mo return -28.8%
3-mo return -32.1%
avg daily vol. 211.02T
52-week high 14.2
52-week low 6.03
market cap. $517M
forward pe -
annual div. -
roe -56.9%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 70.2%
baraka

Subscribe now for daily local and international financial news

Subscribe